Skip to content


Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin. Pradaxa's patents are valid until 2031-01-20 (FDA).
Trade Name Pradaxa
Common Name Dabigatran
Indication replacement arthroplasty, venous thromboembolism
Drug Class Thrombin inhibitors (argatroban type)
Get full access now